These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16567968)

  • 21. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of STI571 (gleevec) on pancreatic cancer cell growth.
    Li J; Kleeff J; Guo J; Fischer L; Giese N; Büchler MW; Friess H
    Mol Cancer; 2003 Sep; 2():32. PubMed ID: 14521721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
    Altuna X; Lopez JP; Yu MA; Arandazi MJ; Harris JP; Wang-Rodriguez J; An Y; Dobrow R; Doherty JK; Ongkeko WM
    Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
    Prunotto M; Bosco M; Daniele L; Macri' L; Bonello L; Schirosi L; Rossi G; Filosso P; Mussa B; Sapino A
    Lung Cancer; 2009 May; 64(2):244-6. PubMed ID: 19041155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
    Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
    Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
    Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
    Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.
    Re D; Wickenhauser C; Ahmadi T; Buchdunger E; Kochanek M; Diehl V; Wolf J
    Br J Cancer; 2002 Apr; 86(8):1333-5. PubMed ID: 11953894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
    Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM; Liu JC
    J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
    Jakubowska J; Stasiak M; Szulawska A; Bednarek A; Czyz M
    Acta Biochim Pol; 2007; 54(4):839-46. PubMed ID: 17957275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
    Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
    Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
    Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.